Ads
related to: iga kidney disease treatment- PROTECT Study
Explore The Data.
Learn About the Outcomes.
- Mechanism of Action
See the Pathophysiology of IgA
Nephropathy and How it Works.
- Request a Representative
Learn About a Treatment Option.
Connect With a Representative.
- Official Patient Website
Visit Our Official Patient Website
for More Information.
- PROTECT Study
amazon.com has been visited by 1M+ users in the past month
Search results
Results from the WOW.Com Content Network
IgA nephropathy (IgAN), also known as Berger's disease (/ b ɛər ˈ ʒ eɪ /) (and variations), or synpharyngitic glomerulonephritis, is a disease of the kidney (or nephropathy) and the immune system; specifically it is a form of glomerulonephritis or an inflammation of the glomeruli of the kidney. Aggressive Berger's disease (a rarer form of ...
English: What is IgA nephropathy? IgA nephropathy, sometimes called Berger disease, is a type of nephritic syndrome where abnormal IgA antibody is formed, which results in immune complex deposition in the glomerular mesangium, leading to kidney disease. This video covers the pathophysiology, signs and symptoms, and treatment of IgA nephropathy.
(Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease, the health regulator's ...
Kidney failure is known as the end-stage of kidney disease, where dialysis or a kidney transplant is the only treatment option. Chronic kidney disease is defined as prolonged kidney abnormalities (functional and/or structural in nature) that last for more than three months. [1]
Sparsentan was approved in the US under accelerated approval based on reduction of proteinuria. [2] [6] [13] In September 2024, the US FDA converted the conditional approval in the kidney disease IgA nephropathy (IgAN) into a full approval based on positive long-term confirmatory results from the PROTECT Study demonstrating that sparsentan significantly slowed kidney function decline over two ...
Povetacicept is in phase 3 testing as a treatment for IgA nephropathy, a chronic kidney disease. VX-880 is Vertex's most advanced candidate that holds the potential to cure type 1 diabetes.
Ads
related to: iga kidney disease treatmentamazon.com has been visited by 1M+ users in the past month